Aberrant vascular architecture in tumors and its importance in drug-based therapies.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Drug Discovery Today

• Publication date

  2003-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1359-6446(03)02686-2PMID 12706657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endothelial Cells of Tumor Vessels: Abnormal but not Absent

  2004cited by this paper
• Vascularization of tumors: A review

  2004cited by this paper
• Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes

  2004cited by this paper
• Transport of molecules across tumor vasculature

  2004cited by this paper
• Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy.

  2003cited by this paper
• ECM Remodeling Regulates Angiogenesis: Endothelial Integrins Look for New Ligands

  2002cited by this paper
• Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

  2002cited by this paper
• Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.

  2002cited by this paper
• Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

  2002cited by this paper
• Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors.

  2002cited by this paper
• Tumour biology: Herceptin acts as an anti-angiogenic cocktail

  2002cited by this paper
• The development of combretastatin A4 phosphate as a vascular targeting agent.

  2002cited by this paper
• Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices

  2002cited by this paper
• Specialization of tumour vasculature

  2002cited by this paper
• Clinical translation of angiogenesis inhibitors

  2002cited by this paper
• Analysis of Mural Cell Recruitment to Tumor Vessels

  2002cited by this paper
• Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics

  2002cited by this paper
• Vascular Morphogenesis and Remodeling in a Model of Tissue Repair: Blood Vessel Formation and Growth in the Ovarian Pedicle After Ovariectomy

  2001cited by this paper
• Vascular Morphogenesis and Remodeling in a Human Tumor Xenograft: Blood Vessel Formation and Growth After Ovariectomy and Tumor Implantation

  2001cited by this paper
• Mouse by Rofecoxib , a Specific Cyclooxygenase-2 Inhibitor 716 ∆ Apc Chemoprevention of Intestinal Polyposis in the Updated Version

  2001cited by this paper
• In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy

  2001cited by this paper
• Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue

  2001cited by this paper
• Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry

  2001cited by this paper
• Kinetics of placenta growth factor/vascular endothelial growth factor synergy in endothelial hydraulic conductivity and proliferation.

  2001cited by this paper
• Adhesion events in angiogenesis.

  2001cited by this paper
• Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

  2001cited by this paper
• Vascular endothelial growth factor and vascular targeting of solid tumors.

  2001cited by this paper
• Integrins as targets of angiogenesis inhibition.

  2001cited by this paper
• Cellular interactions in vascular growth and differentiation.

  2001cited by this paper
• In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy

  2001cited by this paper
• Openings between defective endothelial cells explain tumor vessel leakiness.

  2000cited by this paper
• Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood.

  2000cited by this paper
• Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.

  2000cited by this paper
• Vasculogenic mimicry: how convincing, how novel, and how significant?

  2000cited by this paper
• Vasculogenic mimicry in tumors. Fact or artifact?

  2000cited by this paper
• Tumor infarction by targeting tissue factor to tumor vasculature.

  2000cited by this paper
• Effect of vascular endothelial growth factor on cultured endothelial cell monolayer transport properties.

  2000cited by this paper
• Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis.

  2000cited by this paper
• Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.

  2000cited by this paper
• Vasculogenic mimicry and tumor angiogenesis.

  2000cited by this paper
• The biology of cell locomotion within three-dimensional extracellular matrix

  2000cited by this paper
• Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.

  1999cited by this paper
• Fibronectin and its integrin receptors in cancer.

  1999cited by this paper
• Endostatin: A Promising Drug for Antiangiogenic Therapy

  1999cited by this paper
• Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.

  1999cited by this paper
• Effect of local anti-VEGF antibody treatment on tumor microvessel permeability.

  1999cited by this paper
• The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

  1999cited by this paper
• Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.

  1999cited by this paper
• Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.

  1999cited by this paper
• The next frontier of molecular medicine: Delivery of therapeutics

  1998cited by this paper
• Natural Products as Angiogenesis Inhibitors

  1998cited by this paper
• Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.

  1998cited by this paper
• Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4.

  1998cited by this paper
• Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display.

  1998cited by this paper
• Tumor induction of VEGF promoter activity in stromal cells.

  1998cited by this paper
• Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

  1997cited by this paper
• Neovasculature induced by vascular endothelial growth factor is fenestrated.

  1997cited by this paper
• Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis.

  1997cited by this paper
• Effect of host microenvironment on the microcirculation of human colon adenocarcinoma.

  1997cited by this paper
• During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium.

  1996cited by this paper
• The vesiculo‐vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation

  1996cited by this paper
• Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis.

  1996cited by this paper
• During angiogenesis, vascular endothelial growth factor regulate natural killer cell adhesion to tumor endothelium

  1996cited by this paper
• Delivery of Molecular Medicine to Solid Tumors

  1996cited by this paper
• Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.

  1996cited by this paper
• Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.

  1995cited by this paper
• Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor.

  1995cited by this paper
• Extracellular matrix as a solid-state regulator in angiogenesis: identification of new targets for anti-cancer therapy.

  1992cited by this paper
• Intussusceptive microvascular growth, a new mechanism of capillary network formation.

  1992cited by this paper
• Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions.

  1991cited by this paper
• Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy.

  1990cited by this paper
• Determinants of tumor blood flow: a review.

  1988cited by this paper
• Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.

  1986cited by this paper
• The fine structure of tumor blood vessels. I. Participation of non-endothelial cells in tumor angiogenesis.

  1985cited by this paper
• The growth of the blood supply to melanoma transplants in the hamster cheek pouch.

  1966cited by this paper

• Cancer-on-a-chip for precision cancer medicine

  2025cites this paper
• Performance of grayscale combined with contrast-enhanced ultrasound in differentiating benign and malignant pediatric ovarian masses

  2024cites this paper
• SpinFlowSim: A blood flow simulation framework for histology-informed diffusion MRI microvasculature mapping in cancer

  2024cites this paper
• Why do certain cancer cells alter functionality and fuse?

  2023cites this paper
• Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery.

  2023cites this paper
• Endothelial cells metabolically regulate breast cancer invasion toward a microvessel

  2023cites this paper
• Evaluating Tumor Hypoxia Radiosensitization Via Electron Paramagnetic Resonance Oxygen Imaging (EPROI)

  2023cites this paper
• A computational study of famciclovir derivatives against thymidine kinase as a molecular target for the development of novel anticancer drugs via suicide gene therapy concepts.

  2023cites this paper
• Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer

  2023cites this paper
• Prospects in the use of gold nanoparticles as cancer theranostics and targeted drug delivery agents

  2022cites this paper
• Sound-based assembly of a microcapillary network in a saturn-like tumor model for drug testing

  2022cites this paper
• Immune Cell Membrane-Coated Biomimetic Nanoparticles for Targeted Cancer Therapy.

  2021cites this paper
• Engineering strategies to capture the biological and biophysical tumor microenvironment in vitro.

  2021cites this paper
• Microfluidic Reconstitution of Tumor Microenvironment for Nanomedical Applications

  2021cites this paper
• Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment

  2020cites this paper
• Targeting tumor interstitial fluid pressure: will it yield novel successful therapies for solid tumors?

  2019cites this paper
• Oncolytic Bacteria and their potential role in bacterium-mediated tumour therapy: a conceptual analysis

  2019cites this paper
• Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model

  2018cites this paper
• Cancer metabolism gets physical

  2018cites this paper
• α- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models in vivo.

  2018cites this paper
• Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics.

  2018cites this paper
• Multimodal imaging of the tumor microenvironment and biological responses to immune therapy

  2018cites this paper
• Preoperative Ultrasonographic Evaluation for Malignancy of Soft-Tissue Sarcoma: A Retrospective Study

  2018cites this paper
• Preoperative evaluation of intraoperative blood loss during malignant soft tissue tumor resection by ultrasonography.

  2018cites this paper
• Bacteriophage Fusion Peptides Based Targeted Delivery of Therapeutics to Cancer Cells

  2018cites this paper
• Research report 2016

  2017cites this paper
• An overview on recent new nano-anti-parasitological findings and application

  2017cites this paper
• Response-Derived Input Function Estimation for Dynamic Contrast-Enhanced MRI Demonstrated by Anti-DLL4 Treatment in a Murine U87 Xenograft Model

  2017cites this paper
• Tumor Microenvironment on a Chip: The Progress and Future Perspective

  2017cites this paper
• Preclinical evaluation of paramagnetic temperature sensitive liposomes for image-guided drug delivery

  2017cites this paper
• Normalizing aberrant vasculature characteristics generated by elevated extracellular matrix stiffness

  2017cites this paper
• Current Status and Characteristics of Cancer

  2017cites this paper
• Internalization and cytotoxicity effects of carbon-encapsulated iron nanoparticles in murine endothelial cells: Studies on internal dosages due to loaded mass agglomerates.

  2016cites this paper
• Iron(III)-Based Magnetic Resonance–Imageable Liposomal T1 Contrast Agent for Monitoring Temperature-Induced Image-Guided Drug Delivery

  2016cites this paper
• Nanoparticles as Drug Delivery Vehicles

  2016cites this paper
• Implantable tissue isolation chambers for analyzing tumor dynamics in vivo.

  2016cites this paper
• 99mTc-phytate as a diagnostic probe for assessing inflammatory reaction in malignant tumors

  2015cites this paper
• Microfluidic model of angiogenic sprouting.

  2015cites this paper
• Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence

  2015cites this paper
• The challenges facing block copolymer micelles for cancer therapy: In vivo barriers and clinical translation.

  2015cites this paper
• Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid

  2015cites this paper
• Drug Delivery with Organic Solvents or Colloidal Dispersed Systems

  2015cites this paper
• Matrix stiffening in the formation of blood vessels

  2014cites this paper
• Anatomical and Physicochemical Factors Controlling Nanoparticle Pharmacokinetics

  2014cites this paper
• Futuristic and potential phase of nanomedicine

  2014cites this paper
• Neem Leaf Glycoprotein Prophylaxis Transduces Immune Dependent Stop Signal for Tumor Angiogenic Switch within Tumor Microenvironment

  2014cites this paper
• Targeting tumor hypoxia in nasopharyngeal carcinoma

  2013cites this paper
• Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.

  2013cites this paper
• Long-circulating, pH-sensitive liposomes versus long-circulating, non-pH-sensitive liposomes as a delivery system for tumor identification.

  2013cites this paper
• A prolonged release in situ reconfiguring device for the delivery of drugs to solid tumors

  2013cites this paper
• Novel approaches for the measurement of tumoral pO2 by magnetic resonance methods

  2013cites this paper
• Modeling Tumor Blood Vessel Dynamics

  2013cites this paper
• Targeting Tumor Perfusion and Oxygenation to Improve the Outcome of Anticancer Therapy

  2012cites this paper
• Blood Flow and Tumour-Induced Angiogenesis: Dynamically Adapting Vascular Networks

  2012cites this paper
• Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective.

  2012cites this paper
• Modeling Tumor Vasculature: Molecular, Cellular, and Tissue Level Aspects and Implications

  2012cites this paper
• Targeting tumor perfusion and oxygenation modulates hypoxia and cancer sensitivity to radiotherapy and systemic therapies

  2012cites this paper
• Anastomosis of endothelial sprouts forms new vessels in a tissue analogue of angiogenesis.

  2012cites this paper
• Particulate Systems for Targeting of Macrophages: Basic and Therapeutic Concepts

  2012cites this paper
• Development of a Cancer Vaccine Targeting Tumor Blood Vessels

  2012cites this paper
• Modeling Structural and Functional Adaptation of Tumor Vessel Networks During Antiangiogenic Therapy

  2012cites this paper
• Automating tumor classification with pixel-by-pixel contrast-enhanced ultrasound perfusion kinetics.

  2012cites this paper
• Breast cancer cell-derived matrix supports vascular morphogenesis.

  2012cites this paper
• Imaging tumor hypoxia by magnetic resonance methods

  2011cites this paper
• Hypoxia-Targeted Gene Therapy with Chemotherapy Effects of Combining a Macrophage-Based, Mathematical Modeling Predicts Synergistic Antitumor

  2011cites this paper
• Methylselenocysteine – a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs

  2011cites this paper
• Suicide Gene Therapy by Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK)

  2011cites this paper
• Methodological developments and clinical applications of pharmacokinetic models in contrast-enhanced magnetic resonance perfusion studies

  2011cites this paper
• Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy.

  2011cites this paper
• Nanomedicine: novel approaches in human and veterinary therapeutics.

  2011cites this paper
• Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer

  2011cites this paper
• Tenascin-C in the extracellular matrix promotes the selection of highly proliferative and tubulogenesis-defective endothelial cells.

  2011cites this paper
• Nanotherapeutics to overcome conventional cancer chemotherapy limitations.

  2011cites this paper
• Optimization of Bio-Nano Interface Using Gold Nanostructures as a Model Nanoparticle System

  2011cites this paper
• Fluid forces control endothelial sprouting

  2011cites this paper
• Metallic nanoparticles: technology overview & drug delivery applications in oncology

  2010cites this paper
• Landscape Phage-Targeted Drug Delivery to Breast Cancer Cells

  2010cites this paper
• Modelling the Impact of Pericyte Migration and Coverage of Vessels on the Efficacy of Vascular Disrupting Agents

  2010cites this paper
• MR molecular imaging of tumor vasculature and vascular targets.

  2010cites this paper
• Molecular imaging of neutropilin-1 receptor using photoacoustic spectroscopy in breast tumors

  2010cites this paper
• Effects of Tumor Microenvironment on Hyperthermia, Photodynamic and Nanotherapy

  2009cites this paper
• The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models

  2009cites this paper
• Two Dimensional Modeling and Fractal Characterization of Tumor Vascular Network

  2009cites this paper
• Factors Controlling Pharmacokinetics of Intravenously Injected Nanoparticulate Systems

  2009cites this paper
• Particle and Fibre Toxicology Iron Oxide Nanoparticles Induce Human Microvascular Endothelial Cell Permeability through Reactive Oxygen Species Production and Microtubule Remodeling

  2008cites this paper
• Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug

  2008cites this paper
• Contrast enhanced MRI and intravital fluorescence microscopy indicate improved tumor microcirculation in highly vascularized melanomas upon short-term anti-VEGFR treatment

  2008cites this paper
• Antiangiogenic Strategies in Medulloblastoma: Reality or Mystery

  2008cites this paper
• Intravital imaging of CD8+ T cell function in cancer

  2008cites this paper
• Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors.

  2008cites this paper
• Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

  2008cites this paper
• CHAPTER 15 – Inhibitors of tumor angiogenesis

  2008cites this paper
• Inhibitors of Tumor Angiogenesis

  2008cites this paper
• Chapter 39 – Drug Solubilization with Organic Solvents, or Using Micellar Solutions or Other Colloidal Dispersed Systems

  2008cites this paper
• Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer.

  2007cites this paper
• Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy

  2007cites this paper
• Suicide genes for cancer therapy.

  2007cites this paper
• Passive Targeting of Solid Tumors: Pathophysiological Principles and Physicochemical Aspects of Delivery Systems

  2007cites this paper
• Geometry of Human Vascular System: Is it an Obstacle for Quantifying Antiangiogenic Therapies?

  2007cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 192 Molecular Mechanisms of Action of Histidine-rich Glycoprotein in Angiogenesis Inhibition

  2006cites this paper